Cysteinyl leukotrienes (cysLTs) (LTC~4~, LTD~4~ and LTE~4~) play pivotal roles in cell proliferation, differentiation, migration and regulation of immune responses implicated in a wide variety of disorders, including asthma, allergy, atherosclerosis and cancer[@b1]. CysLTs are products of the 5-lipoxygenase (5-LO) pathway. 5-LO converts arachidonic acid to an unstable intermediate LTA~4~, which is then conjugated to reduced glutathione by leukotriene C~4~ synthase to form LTC~4~. After transport to the extracellular space LTC~4~ is converted to LTD~4~ and then to the terminal product LTE~4~, the most abundant cysLT in biological fluids. The biological actions of cysLTs are mediated by 2 currently identified G-protein coupled receptors (GPCR): cysLT type 1 (CysLT~1~) and 2 (CysLT~2~) receptors. They differ in binding affinities for different cysLTs. CysLT~1~ is recognized as a high-affinity receptor for LTD~4~, whereas CysLT~2~ binds LTC~4~ and LTD~4~ with similar affinity. LTE~4~, the most stable of the cysLTs, binds poorly to the classical CysLT~1~ and CysLT~2~ and is also much less potent than LTC~4~ and LTD~4~ in inducing cellular responses *in vitro*, showing a partial agonistic activity[@b2][@b3][@b4][@b5]. However *in vivo*, it is LTE~4~ that has shown to be the most potent cysLT in eliciting influx of eosinophils and basophils into bronchial mucosa of asthmatic subjects and in enhancing airway responsiveness to histamine and increasing vascular permeability, suggesting the existence of one or more leukotriene receptors that have not been identified to date[@b6][@b7][@b8][@b9][@b10]. The potential presence of such a receptor has been demonstrated in CysLT~1~/CysLT~2~ double knock-out mice[@b11] but human data are lacking.

The observations that asthmatic airways respond with enhanced bronchoconstriction to inhaled cysLTs, especially to LTE~4~ in comparison with normal subjects[@b10] and that infiltration of airways by mast cells is associated with disordered airway function in asthma[@b12] suggest that mast cells could be a potential target cell type expressing a putative receptor preferentially responding to LTE~4~. In fact, the possible existence of such a novel, LTE~4~-activated receptor has been suggested in human mast cells[@b13]. In this study LTE~4~ has been shown to be the most potent of cysLTs in inducing cell proliferation and activation of gene expression in human primary mast cells and LAD2 human mast cell line. LTE~4~-mediated activities were resistant to knockdown of CysLT~1~ and CysLT~2~ but were dependent on PPAR-γ signalling. Another study has suggested that the P2Y12 receptor is required for LTE~4~-mediated responses[@b14] but these observations have not been confirmed[@b15].

In order to identify such a receptor responding to LTE~4~ we studied human mast cells and used transcriptome profiling by microarrays, recombinant GPCR overexpression models and methods analysing GPCR signalling. We characterize LTE~4~ as a fully functional agonist activating human CysLT~1~ and show for the first time that CysLT~1~ expression is critically important for responsiveness to LTE~4~ within a human cell system.

Results
=======

LTE~4~ signals differently in LAD2 and LUVA cells
-------------------------------------------------

LTE~4~ has been shown to induce potent responses in LAD2 cells[@b13] offering a model for identification of the elusive receptor responsible for LTE~4~ signalling. In order to compare responses between LTD~4~ and LTE~4~ microarray analysis of LAD2 cells stimulated with either vehicle control, LTD~4~ or LTE~4~ was carried out in the presence of L-cysteine (3 mmol/L) to inhibit dipeptidase enzyme responsible for converting LTD~4~ to LTE~4~[@b16]. Both leukotrienes significantly regulated expression of 64 genes including many chemokines, growth and transcription factors ([Fig. 1A](#f1){ref-type="fig"} and [supplementary Table 1](#S1){ref-type="supplementary-material"}). LTE~4~ was more potent in up and down regulation of gene expression than LTD~4~ for the majority of analysed genes, providing strong evidence for a robust LTE~4~ response in LAD2 cells. CCL4 and CSF2 were among the most upregulated genes in LAD2 cells and were selected for further analysis. qRT-PCR and ELISA analysis of LAD2 cells showed induction of CCL4 and CSF2 with LTE~4~ consistently matching or being the more potent of the 2 ligands ([Fig. 1B](#f1){ref-type="fig"}). To verify whether this responsiveness to LTE~4~ is characteristic for other mast cells, another human mast cell line, LUVA, was analysed to compare responses to LTD~4~ and LTE~4~. Although in LUVA cells LTD~4~ regulated gene expression in a similarly potent way to LAD2 cells, LTE~4~ induced only very weak responses ([Fig. 1C](#f1){ref-type="fig"}). As intracellular calcium mobilisation is a secondary messenger signalling cue for classical leukotriene receptors, cysLT induced calcium mobilisation was analysed in both cell lines. In LAD2 cells, all cysLTs induced a concentration-dependent calcium mobilisation ([Fig. 1D](#f1){ref-type="fig"}), with LTD~4~ and LTC~4~ showing similar potency (LTC~4~ EC~50~−1.3 × 10^−9^ M, LTD~4~ EC~50~−0.58 × 10^−9 ^M) and LTE~4~ being the weakest of all 3 ligands but still inducing a robust response (LTE~4~ EC~50~−1.67 × 10^−9 ^M). In contrast, LTD~4~ was the most potent ligand in LUVA cells (EC~50~−2.8 × 10^−9 ^M) followed by LTC~4~ (EC~50~−1.7 × 10^−8 ^M), while LTE~4~ induced very weak response (EC~50~-not determined)([Fig. 1E](#f1){ref-type="fig"}). Similar potencies of cysLTs as in LUVA cells were detected in HEK293T cells transfected with human CYSLTR1 ([Fig. 1F](#f1){ref-type="fig"}) (LTC~4~ EC~50~−1.12 × 10^−8 ^M, LTD~4~ EC~50~−0.9 × 10^−9 ^M; LTE~4~ EC~50~−8.32 × 10^−8 ^M). Therefore LAD2 and LUVA cells represent two human mast cell lines that respond differently to LTE~4~ stimulation.

Comparison of GPCR gene expression profiles between LAD2 and LUVA cells
-----------------------------------------------------------------------

A previous study[@b13] has suggested that in LAD2 cells LTE~4~ signals through a novel, CysLT~3~ receptor, different from classical CysLT~1~ and CysLT~2~. As our observations in LAD2 and LUVA cells indicated that a potential LTE~4~ receptor should be differentially expressed in LAD2 and LUVA cells, gene expression was compared between LAD2 and LUVA cells using microarray in order to identify the putative gene. A list of significantly differentially expressed genes (ANOVA p \< 0.05; \>2 fold difference) was generated and GPCR genes were filtered using the IUPHAR GPCR database[@b17]. Among 27 GPCRs that differed significantly in expression between LAD2 and LUVA cells ([Fig. 2A](#f2){ref-type="fig"}, [supplementary Table 2](#S1){ref-type="supplementary-material"}), 10 GPCRs were considered orphan receptors (without known ligands)(GPR12, GPR37, GPR65, GPR85, GPR114, GPR137B, GPR174, MAS1L, MRGPRX2 and P2RY8). GPR65, MAS1L and MRGPRX2 were the most differentially expressed orphan GPCRs (9.9, 32.4 and 70.2 fold difference between LAD2 and LUVA cells, respectively). To ascertain whether cysLTs, and LTE~4~ in particular, could mediate signalling through any of these receptors, plasmids encoding GPR65, MAS1L and MRGPRX2 were transiently transfected into HEK293T cells and calcium mobilisation was analysed upon stimulation with cysLTs ([Fig. 2B](#f2){ref-type="fig"}). CYSLTR1 gene was among differentially expressed GPCRs and was used as a positive control for all experiments. No specific calcium responses were observed in any of the transfectants apart from cells transfected with CYSLTR1, which showed the predicted pattern of response to cysLTs. As co-transfections of GPCRs and Gα~16~ have been reported previously to direct signal transduction to phospholipase C and calcium signalling[@b18], target genes were co-expressed with human Gα~16~ and responses to cysLTs measured using calcium mobilisation in order to analyse potential alternative GPCR signalling pathway. Similarly, no response was observed in any of our overexpression models apart from CYSLTR1 transfected cells ([Fig. 2C](#f2){ref-type="fig"}). Thus CysLT~1~ was the receptor that was differentially expressed in LAD2 and LUVA cells (4.3 fold difference) and responded to cysLTs.

CysLT~1~ is required for LTE~4~ induced signalling in LAD2 cells
----------------------------------------------------------------

To determine whether CysLT~1~ could be involved in LTE~4~ signal transduction, LAD2 and LUVA cells were pretreated with selective CysLT~1~ and CysLT~2~ antagonists, Montelukast and HAMI3379, respectively. Antagonists' selectivity was previously verified in HEK293T cell transfection models ([supplementary Figure 1](#S1){ref-type="supplementary-material"}). qRT-PCR analysis of CCL4 gene expression in LAD2 cells showed that both LTD~4~ and LTE~4~ induced responses were fully inhibited by Montelukast while HAMI3379 had no effect ([Fig. 2D](#f2){ref-type="fig"}). In LUVA cells, LTD~4~ signalling was again fully inhibited by Montelukast but not by HAMI3379 ([Fig. 2E](#f2){ref-type="fig"}). Analysis of calcium mobilisation in these cells showed a very similar picture, with Montelukast fully inhibiting LTE~4~ responses in LAD2 as well as LTD~4~ responses in LAD2 and LUVA cells while HAMI3379 had no effect ([Fig. 2D,E](#f2){ref-type="fig"}). To verify whether the potent LTE~4~ induced, Montelukast sensitive, response in LAD2 cells was attributable specifically to CysLT~1~ signalling and not via another Montelukast sensitive receptor, stable CYSLTR1 receptor knockdown was generated in LAD2 cells using shRNA. Four shRNA targeting different regions of CYSLTR1 were transduced into separate LAD2 cell populations using lentiviral particles. qRT-PCR analysis of CYSLTR1 revealed shRNA "475" to significantly knock down CYSLTR1, without affecting CYSLTR2 mRNA expression ([supplementary Figure 2](#S1){ref-type="supplementary-material"}). Knocking down of CYSLTR1 substantially inhibited intracellular calcium responses to LTD~4~ and LTE~4~ ([Fig. 3A,B](#f3){ref-type="fig"}), confirming a functional decrease in CysLT~1~ expression. CCL4 and CSF2 mRNA and protein expression upon LTD~4~ and LTE~4~ stimulation were almost completely abrogated in CysLT~1~ knocked down LAD2 cells ([Fig. 3C,D](#f3){ref-type="fig"} and [supplementary Figure 3](#S1){ref-type="supplementary-material"}) identifying CysLT~1~ as a receptor responsible for LTE~4~ induced signalling in LAD2 cells.

Overexpression of CysLT~1~ in LUVA cells does not determine LTE~4~ responses
----------------------------------------------------------------------------

Our GPCR expression profiles identified CYSLTR1 as more highly expressed in LAD2 than in LUVA cells. To test the hypothesis that the expression level of CYSLTR1 is relevant for mast cell responsiveness to LTE~4~, CYSLTR1 was stably overexpressed in LUVA cells using lentiviral transduction and positive clones were selected using puromycin. qRT-PCR confirmed a 3-fold increase in CYSLTR1 expression in the transduced population, a level similar to LAD2 cells ([Fig. 3E](#f3){ref-type="fig"}). Functional CYSLTR1 overexpression was confirmed using calcium assay and showed potent concentration-dependent increase in LTE~4~ induced calcium responses ([Fig. 3F](#f3){ref-type="fig"}), again similar to responses observed in LAD2 cells. Stimulation of LUVA cells overexpressing CysLT~1~ and control empty vector-transduced cells with either LTD~4~ or LTE~4~ revealed no significant differences in CCL4 mRNA or protein induction between both cell lines ([Fig. 3G,H](#f3){ref-type="fig"}), showing that the expression level of CysLT~1~ does not solely determine LTE~4~ induced gene regulation, even though it allows for enhanced calcium mobilisation in response to LTE~4~.

Comparison of CYSLTR1 gene sequence between LAD2 and LUVA cells
---------------------------------------------------------------

As genetic variations in the CYSLTR1 gene between LAD2 and LUVA cells could account for such differential responses to LTE~4~, promoter and coding regions of CYSLTR1 in both cell types were sequenced. DNA was extracted and CYSLTR1 promoter fragment containing 4 single nucleotide polymorphisms (SNPs)(rs321029, rs2637204, rs2806489, rs7066737) as well as the entire coding region were PCR amplified and sequenced. BLAST analysis of DNA sequences from LAD2 and LUVA cells revealed no differences between cell lines and showed that both cell lines share the same promoter homozygous haplotype, "CAAC" for 4 SNPs studied, respectively and homozygous T allele for rs320995 coding synonymous SNP. Human CYSLTR1 gene is localized to chromosome X thus lack of heterozygosity at the locus was consistent with the fact that both cell lines were derived from male donors.

CysLT-activated CysLT~1~ signals through Gαq, calcium and Erk for gene regulation
---------------------------------------------------------------------------------

In order to compare CysLT~1~ mediated signalling in LAD2 and LUVA, both cell types were pre-incubated with several signalling pathway inhibitors and gene expression was measured in response to LTD~4~ and LTE~4~ ([Fig. 4A,B](#f4){ref-type="fig"}). LTD~4~- and LTE~4~-induced CCL4 mRNA expression was potently inhibited by U0126 (MEK/Erk pathway inhibitor), intracellular (BAPTA-AM) and extracellular (EDTA) calcium chelators but was not modified by pertussis toxin or GW9662 and T0070907 (PPAR-γ inhibitors), suggesting that in both cell lines CysLT~1~ couples to Gαq, requires intracellular and extracellular calcium and Erk activation for regulation of gene expression.

LTE~4~ activates prolonged signalling in LAD2 cells
---------------------------------------------------

To further analyse the agonistic activity of LTE~4~, time course experiments of Erk phosphorylation were conducted and analysed by Western blotting ([Fig. 4C](#f4){ref-type="fig"}). In LAD2 cells stimulated with LTD~4~, Erk phosphorylation peaked at 7 minutes with a gradual decrease until 60 minutes. LTE~4~ induced a peak of Erk phosphorylation later but with a more sustained phosphorylation, still being detectable after 60 minutes. In LUVA cells the time point of highest Erk phosphorylation was similar to LAD2 cells but LTE~4~-induced Erk phosphorylation was shorter than in LAD2 cells. Thus sustained Erk phosphorylation induced by LTE~4~ in LAD2 but not in LUVA cells underlies an important difference in CysLT~1~-mediated responses between the cell lines.

We next compared calcium mobilisation kinetics in LAD2 cells; although LTD~4~ induced a higher peak response than LTE~4~, the intracellular calcium levels decreased at a higher rate after LTD~4~ stimulation while LTE~4~ induced a long lasting plateau phase ([Fig. 4D](#f4){ref-type="fig"}). The sustained calcium signalling in response to LTE~4~ was not observed in LUVA cells or in LUVA cells overexpressing CysLT~1~ ([Fig. 4D](#f4){ref-type="fig"}).

As GPCR signalling is regulated through receptor desensitization, cross desensitization experiments with cysLTs were performed ([Fig. 4E](#f4){ref-type="fig"}). Prior stimulation with either LTC~4~ or LTD~4~ completely abrogated calcium response to LTD~4~ in LAD2 and LUVA cells, suggesting that both LTC~4~ and LTD~4~ can fully desensitize CysLT~1~ in both cell lines. However, prior stimulation with LTE~4~ caused only partial inhibition of the calcium response to LTD~4~ in LAD2 and LUVA cells, showing partial agonistic/desensitizing activity of LTE~4~ but no difference between the cell lines in LTE~4~ mediated signalling. The sustained increased level of calcium in LAD2 but not in LUVA cells after LTE~4~ stimulation was again the main difference observed between the cell lines in these experiments.

To analyse whether prolonged calcium/Erk signalling induced by LTE~4~ in LAD2 cells affects gene expression, CCL4 mRNA expression was analysed in LAD2 and LUVA cells after short (5 minutes) and long (2 hours) term exposure to LTD~4~ and LTE~4~, respectively. In LAD2 cells, 2 hour exposure to LTE~4~ and LTD~4~, caused similar upregulation of CCL4 mRNA expression ([Fig. 4F](#f4){ref-type="fig"}). Stimulation of LAD2 cells with LTE~4~ for only 5 minutes failed to induce potent CCL4 expression with mRNA levels being significantly lower than that induced by LTD~4~. In LUVA cells, no difference could be observed between different exposure times.

Discussion
==========

This study identifies LTE~4~ as a fully functional agonist activating human CysLT~1~ for regulation of gene expression in LAD2 cells although only weak, partial agonism of LTE~4~ signalling could be detected in LUVA cells. Our data suggest that increased expression of CysLT~1~ and induction of prolonged intracellular signalling are required for LTE~4~ functional agonism. Ever since the elucidation and cloning of human CysLT~1~ and CysLT~2~, LTE~4~ has been considered as a final, non-active leukotriene metabolite due to its weak efficacy in recombinant systems and poor binding affinities compared to LTC~4~ and LTD~4~[@b6]. However, it was LTE~4~ that was shown to be the most potent cysLT in inducing inflammatory and contractile responses in asthmatic subjects. Our observation that LTE~4~ can induce full agonistic activity through CysLT~1~ could be of relevance for explaining this discrepancy between potent *in vivo* activity of LTE~4~ observed in asthmatic patients and weak *in vitro* potency for classical cysLT receptors. Early studies analysing the effects of cysLTs *in vivo* revealed a disproportionate augmentation in relative responses to LTE~4~ inhalation in asthmatic patients when compared to healthy individuals[@b10]. LTE~4~ responsiveness was increased more than 200 fold in asthmatics while responses to LTC~4~ and LTD~4~ were increased 6 and 9 fold respectively. More recent clinical studies suggest that CysLT~1~ is more highly expressed in asthmatic airways compared to healthy individuals[@b19], with further increase observed in asthma exacerbations and in a sub-phenotype of asthma, patients with aspirin-exacerbated respiratory disease (AERD)[@b20][@b21]. This increased CysLT~1~ expression observed in AERD patients was significantly decreased following successful aspirin desensitisation, a procedure associated also with a significant reduction in sensitivity to inhaled LTE~4~[@b20]. We found similar disproportionate augmentation in LTE~4~-induced responses when comparing LAD2 and LUVA cells, a model of relatively high versus low CysLT~1~ expression. LTC~4~ and LTD~4~ were 2--3 times more potent at inducing calcium mobilisation in LAD2 cells compared to LUVA while LTE~4~ showed nearly 60-fold difference. Such potent responses to cysLTs, including LTE~4~ have been recently described in other human primary cells expressing high levels of CysLT~1~, T helper type 2 (Th2) lymphocytes[@b22][@b23] and group 2 innate lymphoid cells (ILC2)[@b24] supporting further our observation.

Prolonged intracellular signalling was identified as another potential contributing factor for the potency of LTE~4~ responses. The sustained increase in intracellular calcium and Erk phosphorylation upon LTE~4~ stimulation were observed in LAD2 but not in LUVA cells, suggesting that prolonged signalling could be critical for transcriptional regulation. LTE~4~, in contrast to LTC~4~ and LTD~4~, shows only partial activity and does not desensitise CysLT~1~ responses, a feature that can contribute to prolonged signalling in response to LTE~4~ in LAD2 cells. In fact, in experiments with short term exposure to agonists LTE~4~ showed only weak, partial agonist activity in comparison to LTD~4~, confirming important role of prolonged signalling in LTE~4~ induced responses. Overexpression of CysLT~1~ in LUVA did not restore sustained intracellular calcium and full agonism even though it increased peak calcium response to LTE~4~, suggesting that additional unidentified signalling molecules expressed in LAD2 cells but not in LUVA, are also required for full functional agonism of LTE~4~.

Mouse models provide strong evidence that CysLT~1~ and CysLT~2~ are not the only cysLT receptors as germline deletion did not diminish leukotriene-mediated inflammation[@b11][@b14][@b25]. Our data presented here provide an explanation for potent LTE~4~ activity observed in humans but do not rule out the possibility of another cysLT receptor. Our study shows for the first time that CysLT~1~ expression is critically important for responsiveness to LTE~4~ within a human cell system. This could potentially be relevant for human cell types other than mast cells and could thus have important implications for diagnostics and targeted treatment of specific phenotypes of asthma.

Materials and Methods
=====================

Reagents
--------

Leukotrienes (LTC~4~, LTD~4~ and LTE~4~), Montelukast, MK-571, HAMI3379, U-0126, GW9662, T0070907 (all Cayman Chemical), EDTA (Ambion), BAPTA-AM, Pertussis Toxin, Calcium ionophore (A23187), (all Sigma-Aldrich) were obtained from the manufacturers.

Cell Culture
------------

HEK293T cells were cultured in DMEM medium supplemented with 2 mmol/L glutamine, 10% fetal bovine serum and Penicillin/Streptomycin (50 units/ml) (all Life Technologies) in a humidified 5% CO~2~ 37 ^o^C incubator. LAD2 cells (a kind gift from Dr. Arnold Kirshenbaum, NIAID, NIH, USA[@b26]) and LUVA cells (a kind gift from Dr. John Steinke, University of Virginia, USA[@b27]) were cultured in StemPro-34 medium supplemented with with L-glutamine (2 mmol/L), Pen/Strep (50 IU/ml) and with or without stem cell factor (SCF) (100 ng/ml) (all Life Technologies), respectively. Cells were hemidepleted weekly with fresh medium.

Transient transfections
-----------------------

HEK293T cells cultured to above 60% confluence were transiently transfected as described previously[@b4][@b15] with a mixture of Lipofectamine 2000 (Life Technologies) and the following plasmids as indicated: pcDNA3.1-empty, pcDNA3.1-human CYSLTR1, pcDNA3.1-human CYSLTR2, pcDNA3.1-human GPR65, pcDNA3.1-human GNA15 (Gα~16~) (all the Missouri S&T cDNA Resource Center, Rolla, Mo) and pCMV6-Kan/Neo- human MAS1L and human MRGPRX2 (Origene Technologies) in serum-free medium (Opti-MEM, Life Technologies) according to manufacturer's protocol. After incubation the transfection medium was removed and HEK293T cells were cultured for 36 hours before calcium mobilisation was assayed in response to stimulation with calcium ionophore (1μmol/L), LTC~4~, LTD~4~ and LTE~4~ (all 100 nmol/L).

Short hairpin RNA (shRNA) knockdown
-----------------------------------

For stable gene silencing shRNA constructs targeting different regions of human CYSLTR1 (clone ID: V3LHS_305475, V3LHS_305478, V2LHS_90946 and V2LHS_90947) were purchased from ThermoScientific and used to generate lentiviral particles with the lentiviral packaging system (psPAX2, pMD2.G and PEG-it™ precipitation)(System Biosciences) according to manufacturer's protocol. LAD2 cells were transduced with viral particles for 24 hours and positive cells selected using Puromycin (2μg/ml)(Life Technologies). Efficiency of transduction was assessed by analysing GFP expression using flow cytometry.

CYSLTR1 overexpression
----------------------

CYSLTR1 gene was amplified from the pcDNA3.1-CYSLTR1 construct (UMR cDNA Resource Center) with primers containing restriction enzyme sites for NheI and BamHI (5′-AGGTGCTAGCATGGATGAAACAGGAAATT and 5′-GCGGGGATCCCTATACTTTACATATTTC) and cloned into lentiviral vector pCDH (System Biosciences) encoding GFP and puromycin resistance under the EF1 promoter and a multiple cloning site under the CMV promoter. Viral particles were generated using lentiviral packaging system (System Biosciences). LUVA cells were transduced, selected with puromycin (2μg/ml) and transduction efficiency was evaluated by GFP expression using flow cytometry.

DNA sequencing
--------------

Total DNA was extracted using DNeasy Tissue kit (Qiagen) and fragments of CYSLTR1 gene were amplified using Platinum Taq Polymerase High Fidelity (Invitrogen) following manufacturer's protocol and primers: CYSLTR1 promoter 5′-AACTGGAGACTTGCAGGTTGCG, 5′-AACATCAAAGTGCTGCCCCAGG; CYSLTR1 coding region 5′-TCAATGCCTCACTACTATTGCTTG, 5′-TTGGTTTGGACTGGAAATGGG and sequenced by Source Bioscience Sanger service using custom designed primers: CYSLTR1 promoter 5′-TAAGATGGGAAGCAGGGACG, 5′-GGCTTCAATCAGCACATACC; CYSLTR1 coding region 5′-ATACCAAGTGCTTTGAGCC, 5′-GCATTTGGCTCTTTGGTG and 5′-GTTTGATTGTCTTGTGGGG.

Calcium mobilisation assay
--------------------------

Calcium mobilisation assays were conducted using FLIPR calcium 4 assay kit (Molecular Devices) as described previously[@b4][@b28]. Cells (1.5 × 10^5^/well) were plated into poly-L-lysine coated 96 well plates in RPMI 1640 supplemented with 10 mmol/L HEPES, incubated for 1 hour with FLIPR loading buffer prior to addition of ligand and fluorescent intensity was measured at 37 °C using a Flexstation 3 (Molecular Devices). Controls included medium control with ethanol for leukotriene stimulations. Results were analysed with SoftMax Pro Software (Molecular Devices).

Real time PCR
-------------

LAD2 and LUVA cells were stimulated for 2 hours in the presence of L-cysteine (3 mmol/L) with LTD~4~ and LTE~4~ (both 100 nmol/L) and vehicle control. In some experiments as indicated cells were pretreated with U0126 (1μmol/L; 30 min), BAPTA-AM (30μmol/L; 30 min), EDTA (2.5 mmol/L; 5 min), pertussis toxin (PTX)(100 ng/ml; overnight), GW9662 (10μmol/L; 30 min) or T0070907 (1μmol/L; 30 min). Total cellular RNA was isolated using the miRNeasy mini kit (Qiagen), DNAase treated (Ambion) and reverse transcribed using RevertAid M-MuLV (Fermentas). Expression of mRNA encoding selected genes was measured using real time PCR on an ABI Prism 7900 Sequence Detection System (Applied Biosystems). Commercially available primer probe sets: 18S rRNA - 4319413E (Applied Biosystems) and individually designed assays using the Universal Probe Library (UPL) (Roche): CYSLTR1- probe 71, primers 5′-GGAGAGGGTCAAAGCAACAA, 5′-TGCAGAAGTCCGTGGTCATA; CYSLTR2- probe 21, primers 5′-TGATGTGACACTGCCGTTCT, 5′-TCATGGCTTCCTCAATAATGC; CCL4- probe 20, primers 5′-CAGCACAGACTTGCTTGCTT, 5′-CTTCCTCGCAACTTTGTGGT; CSF2- probe 1, primers 5′-GCCCTTGAGCTTGGTGAG, 5′-TCTCAGAAATGTTTGACCTCC were used. All primers/probes were tested for optimal efficiency of amplification. Relative gene expression was normalized to 18S rRNA. Data were analysed using SDS2.1 software (Applied Biosystems).

Microarray Analysis
-------------------

Total cellular RNA was isolated using the miRNeasy mini kit (Qiagen), DNase treated (Ambion), quality analysed on an Agilent 2100 Bioanalyzer (Agilent Technologies) and further processed with the Ambion WT Expression Kit (Applied Biosystems) according to the manufacturers' instructions[@b29]. cRNA was fragmented, labelled, and hybridised to the Affymetrix Human Gene 1.0 ST Arrays using the Gene Chip WT Terminal Labeling and Hybridization Kit (Affymetrix). GeneChip fluidics station 450 (Affymetrix) was used for processing of the arrays and fluorescent signals were detected with the GeneChip scanner 3000. Images were analysed with the GeneChip operating software (Affymetrix). Further analysis was performed with the Partek Genomics Suite (Partek). RMA processing and quantile normalization was applied, and after Median Polish and gene level probeset summarization, differentially expressed genes were identified using ANOVA. Data were submitted to Gene Expression Omnibus database (accession number [GSE75603](GSE75603)).

Western Blot Analysis
---------------------

Total protein lysates were prepared using lysis buffer containing 1 mM protease inhibitor cocktail (Roche), 25 μg proteins loaded onto a 10% Bis-Tris NuPage gel (Invitrogen) and transferred onto a nitrocellulose membrane (Invitrogen). The membrane was incubated with primary antibodies against phospho-p44/42 MAPK and p44/p42 MAPK (Extracellular-signal-regulated kinase (ERK))(Cell Signaling) overnight at 4 °C, followed by secondary, horseradish peroxidase-conjugated antibody (goat anti rabbit IgG (Southern Biotech). Blots were developed using ECL plus Detection Reagent (GE Healthcare) and visualized on a Chemidoc MP System (BioRad). Data were analysed using Image Lab 4.1 software (BioRad).

ELISA
-----

LAD2 and LUVA cells were stimulated for 6 hours in the presence of L-cysteine (3 mmol/L) with LTD~4~ and LTE~4~ (both 100 nmol/L) and vehicle control. CCL4 and CSF2 concentrations were measured in supernatants using human CCL4 (MIP-1β) and CSF2 (GM-CSF) duo set kits (R&D Systems, UK) following manufacturer's protocol.

Statistical analysis
--------------------

Data were analysed by means of one- or two- way ANOVA using GraphPad Prism software (GraphPad). Differences were considered significant at a p-value of less than 0.05.
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![LTE~4~ is a potent agonist in LAD2 but not in LUVA cells.\
(**A**) LAD2 cells (n = 3) were stimulated with vehicle control, LTD~4~ and LTE~4~ and gene expression was analysed using microarrays. Hierarchical clustering of significantly (ANOVA, p \< 0.05 LTD~4~ and LTE~4~ compared to control, False Discovery Rate = 0.1) regulated genes is presented as a heat map. (**B**) LAD2 and (**C**) LUVA cells were stimulated and CCL4 or CSF2 gene expression were measured at mRNA and protein levels. Data expressed as mean ± SEM from 3 separate experiments. (**D**) LAD2, (**E**) LUVA and (**F**) HEK293T transfected with CYSLTR1 cells were stimulated with indicated concentrations of LTC~4~, LTD~4~ and LTE~4~ and calcium mobilisation was measured. Data from 3 experiments run in triplicate, presented as mean ± SEM of baseline corrected peak intracellular calcium response. Relative fluorescence unit (RFU).](srep20461-f1){#f1}

![Comparison of GPCR gene expression profiles between LAD2 and LUVA cells.\
(**A**) Microarray gene expression was compared in LAD2 and LUVA cells (n = 3) and hierarchical clustering of differentially expressed GPCRs (ANOVA, p \< 0.05, \>2 fold difference) is presented as a heat map. Intracellular calcium mobilisation was analysed in HEK293T cells transiently transfected with the genes of interest (**B**) and co-transfected with Gα16 (**C**). Data expressed as percentage of peak calcium ionophore response, mean ± SEM from 3 experiments run in triplicate. LAD2 (**D**) and LUVA (**E**) cells were pre-treated with Montelukast (100 nmol/L) and HAMI3379 (1 μmol/L) for 10 minutes, stimulated with LTD~4~ and LTE~4~ (both 100 nmol/L) and CCL4 mRNA expression or calcium mobilisation was measured. Data expressed as a fold difference in comparison to vehicle control or as baseline corrected peak calcium response. Mean ± SEM from 3 separate experiments. Relative fluorescence unit (RFU).](srep20461-f2){#f2}

![CysLT~1~ is required for LTE~4~ induced signalling in LAD2 cells.\
Calcium mobilisation responses to LTD~4~ (**A**) and LTE~4~ (**B**) in Empty control (Ctrl) and CYSLTR1 knocked down (CYSLTR1 KD) LAD2 cells. Baseline corrected peak calcium responses from 3 experiments run in triplicate presented as mean ± SEM. (**C**) Control and CYSLTR1 knocked down LAD2 cells were stimulated with vehicle control, LTD~4~ or LTE~4~ for 2 (mRNA) (**C**) or 6 hours (protein) (**D**) before analysis. Data expressed as fold difference in comparison to vehicle control for CCL4 mRNA and as CCL4 supernatant concentrations. Mean ± SEM from 3--5 experiments, relative fluorescence unit (RFU). (**E**) LUVA cells were stably transduced with empty (LUVA-empty) or CYSLTR1 overexpression (LUVA-CYSLTR1) vectors and relative CYSLTR1 mRNA expression was measured and compared to LAD2 cells. Mean ± SEM, n = 6. (**F**) Calcium mobilisation response to a range of LTE~4~ concentrations was evaluated in empty control and CYSLTR1 transduced LUVA cells. Mean ± SEM of baseline corrected peak calcium responses, n = 9. Control empty vector and CYSLTR1 transduced LUVA cells were stimulated as indicated before CCL4 mRNA (**G**) or protein (**H**) expression was measured. Mean ± SEM of 3 separate experiments.](srep20461-f3){#f3}

![LTE~4~ induces sustained signalling in LAD2 cells.\
LAD2 (**A**) and LUVA (**B**) cells were pre-treated with selected inhibitors and stimulated with LTD~4~ or LTE~4~. Data from 3 separate experiments shown as % of LTD~4~-induced CCL4 mRNA expression (mean ± SEM), \*p \< 0.05, \*\*p \< 0.001, ANOVA with Bonferroni post test compared to LTD~4~ or LTE~4~. (**C**) LAD2 and LUVA cells were stimulated for time indicated with vehicle control (Ctrl), LTD~4~ or LTE~4~ (both 100 nmol/L) and phosphorylated Erk and total Erk expression measured using specific antibodies. Results from a representative experiment of 3 performed. Calcium mobilisation traces of LAD2, LUVA or LUVA-CYSLTR1 cells stimulated as indicated with LTD~4~ or LTE~4~ (100 nmol/L) once (**D**) or twice (**E**). Representative of 3 separate experiments, relative fluorescence unit (RFU). Black arrows indicate start of stimulation. (**F**) LAD2 and LUVA cells were exposed for either 5 minutes or 2 hours to vehicle control, LTD~4~ or LTE~4~ (both 100 nmol/L) and CCL4 mRNA measured by qRT-PCR after 2 hours incubation. Mean ± SEM data from 3 experiments shown as a fold change in comparison to controls. \*p \< 0.05, 2-way ANOVA comparison between 5 min LTD~4~ and LTE~4~ stimulations.](srep20461-f4){#f4}
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